FDA Advisors Question Safety and Effectiveness of Diabetes Device, Afrezza
An initial review by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee of the experimental inhaled insulin device Afrezza has raised questions about the product's safety and effectiveness.
No comments:
Post a Comment